NASDAQ : XBIO
Xenetic Biosciences, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 2.12 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 4.97M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 4.92M |
| Enterprise Value | -1.55M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 2.34M |
| Shares Outstanding | 2.34M |
| Shares Change (YoY) | +34.68% |
| Shares Change (QoQ) | +0.14% |
| Owned by Insiders (%) | 7.99% |
| Owned by Institutions (%) | 1.53% |
| Float | 1.89M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.59 |
| Forward PS | n/a |
| PB Ratio | 0.79 |
| P/TBV Ratio | 0.85 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 7.43 |
| Quick Ratio | 7.23 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -47.04% |
| Return on Assets (ROA) | -26.80% |
| Return on Invested Capital (ROIC) | -31.38% |
| Return on Capital Employed (ROCE) | -43.50% |
| Weighted Average Cost of Capital (WACC) | 17.20% |
| Revenue Per Employee | $1.63M |
| Profits Per Employee | -$1.24M |
| Employee Count | 2 |
| Asset Turnover | 0.53 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.35 |
| 52-Week Price Change | -40.12% |
| 50-Day Moving Average | 2.82 |
| 200-Day Moving Average | 2.84 |
| Relative Strength Index (RSI) | 42.03 |
| Average Volume (20 Days) | 27,019 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 10,961 |
| Short Previous Month | 12,868 |
| Short % of Shares Out | 0.47% |
| Short % of Float | 0.58% |
| Short Ratio (days to cover) | 0.07 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 3.26M |
| Gross Profit | 3.26M |
| Operating Income | -2.64M |
| Pretax Income | -2.48M |
| Net Income | -2.48M |
| EBITDA | n/a |
| EBIT | -2.64M |
| Loss Per Share | -$1.19 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 6.47M |
| Total Debt | n/a |
| Net Cash | 6.47M |
| Net Cash Per Share | $2.76 |
| Equity (Book Value) | 6.07M |
| Book Value Per Share | 2.59 |
| Working Capital | 5.76M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -2.31M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | -2.31M |
| FCF Per Share | -$0.99 |
Margins
| Measure | Value |
|---|
| Gross Margin | 100.00% |
| Operating Margin | -81.01% |
| Pretax Margin | -75.91% |
| Profit Margin | -75.91% |
| EBITDA Margin | n/a |
| EBIT Margin | -81.01% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -34.68% |
| Shareholder Yield | -34.68% |
| Earnings Yield | -56.77% |
| FCF Yield | -44.66% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | 49.04% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | May 15, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -36.1 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |